IL6 and COVID-19: In contrast to the ARDS studies, using inflammatory biomarkers for sub-classification of ARDS [27], as well as the most recent COVID-19 studies [28,29], demonstrating that IL-6 correlates with severe and fatal ARDS/COVID-19, we found no differences in serum IL-6 concentrations between Responder and Non-Responder groups.